title: Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.
abstract: Multiple myeloma (MM) remains an incurable disease and further development of novel agents is needed. Because constitutive expression of topoisomerase I (TopoI) in MM cells and the efficacy of SN-38, an active metabolite of irinotecan (CPT-11), have been reported, we investigated the therapeutic potential of CPT-11. Of the eight MM cell lines analyzed, four showed 50% inhibitory concentration values of less than 2 microg/mL for CPT-11 and less than 2 ng/mL for SN-38. This efficacy was partly explained by the high expression level of human carboxylesterase-2 (hCE-2) in MM cells. Interestingly, high expression of hCE-2 represented the nature of normal plasma cells, suggesting that hCE-2 could efficiently generate SN-38 within the plasma cells. As expected, higher sensitivity to CPT-11 was observed in hCE-2-overexpressing U266 cells than mock U266 cells. On the other hand, the expression levels of hCE-1, TopoI, UGT1A and ABCG2 did not seem to be associated with the sensitivity of MM cells to CPT-11. In a murine xenograft model inoculated s.c. with RPMI8226 cells, administration of CPT-11 alone significantly reduced the tumor volume. When a combination of CPT-11 and bortezomib was administered, the subcutaneous tumors completely disappeared. Thus, clinical trials on CPT-11 in patients with relapsed or refractory MM are warranted.
authors.affiliation: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yano
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kayukawa
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Iida
authors.forename: Chiharu
authors.initials: C
authors.lastname: Nakagawa
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Oguri
authors.forename: Takaomi
authors.initials: T
authors.lastname: Sanda
authors.forename: Jianming
authors.initials: J
authors.lastname: Ding
authors.forename: Fumiko
authors.initials: F
authors.lastname: Mori
authors.forename: Asahi
authors.initials: A
authors.lastname: Ito
authors.forename: Masaki
authors.initials: M
authors.lastname: Ri
authors.forename: Atsushi
authors.initials: A
authors.lastname: Inagaki
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kusumoto
authors.forename: Takashi
authors.initials: T
authors.lastname: Ishida
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Komatsu
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Inagaki
authors.forename: Atsushi
authors.initials: A
authors.lastname: Suzuki
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Ueda
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology* / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology; D043182:Carboxylesterase / Q000378:metabolism*; D045744:Cell Line, Tumor; D004264:DNA Topoisomerases, Type I / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D000077146:Irinotecan; D008297:Male; D051379:Mice; D016513:Mice, SCID; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000201:enzymology; D059004:Topoisomerase I Inhibitors; D014162:Transfection; D023041:Xenograft Model Antitumor Assays
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; C517204:CES2 protein, human; D043182:Carboxylesterase; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin
references.citation: Clin Cancer Res. 2002 Aug;8(8):2696-700
references.pmid: 12171903
references.citation: Blood. 2008 Mar 1;111(5):2516-20
references.pmid: 17975015
references.citation: N Engl J Med. 2004 Oct 28;351(18):1860-73
references.pmid: 15509819
references.citation: Cancer Res. 2001 May 1;61(9):3535-40
references.pmid: 11325813
references.citation: Cancer Sci. 2003 Apr;94(4):350-4
references.pmid: 12824903
references.citation: Oncogene. 2005 Oct 20;24(46):6936-44
references.pmid: 16044163
references.citation: Lung Cancer. 2003 Aug;41(2):187-98
references.pmid: 12871782
references.citation: Ann Hematol. 2004 Oct;83(10):658-60
references.pmid: 15278296
references.citation: J Clin Oncol. 1998 Feb;16(2):589-92
references.pmid: 9469346
references.citation: J Clin Oncol. 2008 May 10;26(14):2320-6
references.pmid: 18467723
references.citation: Toxicol In Vitro. 2006 Mar;20(2):163-75
references.pmid: 16271446
references.citation: N Engl J Med. 2003 Jun 26;348(26):2609-17
references.pmid: 12826635
references.citation: Cancer Res. 1991 Aug 15;51(16):4187-91
references.pmid: 1651156
references.citation: Cancer Res. 2000 Mar 1;60(5):1189-92
references.pmid: 10728672
references.citation: Anticancer Res. 2004 Sep-Oct;24(5A):2893-6
references.pmid: 15517893
references.citation: Cancer Res. 1987 Nov 15;47(22):5944-7
references.pmid: 3664496
references.citation: Br J Haematol. 1993 Jan;83(1):68-74
references.pmid: 8094626
references.citation: Clin Cancer Res. 2004 Nov 15;10(22):7529-39
references.pmid: 15569983
references.citation: Haematologica. 2005 Apr;90(4):559-62
references.pmid: 15820958
references.citation: Br J Haematol. 2005 Jun;129(6):755-62
references.pmid: 15953001
references.citation: Int J Hematol. 2003 Apr;77(3):207-12
references.pmid: 12731662
references.citation: Cancer Res. 2004 Dec 1;64(23):8746-53
references.pmid: 15574786
references.citation: J Clin Oncol. 2008 Jun 10;26(17):2895-900
references.pmid: 18539970
references.citation: Cancer Sci. 2006 Mar;97(3):192-8
references.pmid: 16542215
references.citation: Blood. 2003 Mar 15;101(6):2377-80
references.pmid: 12424198
references.citation: Clin Cancer Res. 2002 Aug;8(8):2605-11
references.pmid: 12171891
references.citation: Gan To Kagaku Ryoho. 1990 Jan;17(1):115-20
references.pmid: 2404454
references.citation: Blood. 2006 Oct 1;108(7):2165-72
references.pmid: 16772605
references.citation: Gan To Kagaku Ryoho. 1990 Jan;17(1):121-30
references.pmid: 2297233
references.citation: Clin Cancer Res. 2001 Aug;7(8):2182-94
references.pmid: 11489791
references.citation: Blood. 2004 Jan 1;103(1):20-32
references.pmid: 12969978
references.citation: Br J Haematol. 2004 Aug;126(3):348-54
references.pmid: 15257706
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3892-901
references.pmid: 17679727